News
- Author:
- Laura Nikolaides
Publish date: May 2, 2017
The Food and Drug Administration has granted accelerated approval to the checkpoint inhibitor durvalumab for patients with locally advanced or meta...
News
- Author:
- Laura Nikolaides
Publish date: April 28, 2017
Approval was based on a meaningful and durable overall response rate in a two-arm, open-label, multicenter trial of 222 patients.
News
- Author:
- Laura Nikolaides
Publish date: March 31, 2017
There is a new treatment available for patients who have metastatic epidermal growth factor receptor T790M mutation–positive non–small cell lung ca...
News
- Author:
- Laura Nikolaides
Publish date: March 27, 2017
The indication does not require a suspected or confirmed deleterious BRCA mutation.
News
- Author:
- Laura Nikolaides
Publish date: March 24, 2017
A newly approved drug may help the body’s immune system attack metastatic MCC cells.
News
- Author:
- Laura Nikolaides
Publish date: March 14, 2017
The Food and Drug Administration has approved ribociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with an aromatase inhibitor...
News
- Author:
- Laura Nikolaides
Publish date: February 2, 2017
The recommended dose for advanced urothelial carcinoma is 240 mg intravenously every 2 weeks.
Article
- Author:
- Laura Nikolaides
Publish date: December 19, 2016
Approval of rucaparib (Rubraca), a PARP inhibitor, was based on an objective response rate of 54%, and a median duration of response of 9.2 months,...
Article
- Author:
- Laura Nikolaides
Publish date: December 13, 2016
The FDA reaffirmed its warning on the possible risk of bladder cancer associated with use of the type 2 diabetes drug pioglitazone.
Article
- Author:
- Laura Nikolaides
Publish date: November 22, 2016
.
Article
- Author:
- Laura Nikolaides
Publish date: November 11, 2016
The agency based its approval on an improvement in overall survival shown in the CheckMate-141 trial, which compared nivolumab with the investigato...
Article
- Author:
- Laura Nikolaides
Publish date: October 25, 2016
Pembrolizumab (Keytruda) is now approved to treat patients with metastatic NSCLC whose tumors have high PD-L1 expression, with no EGFR or ALK genom...
Article
- Author:
- Laura Nikolaides
Publish date: October 20, 2016
The FDA has approved the PD-L1 blocking antibody atezolizumab for the treatment of patients with metastatic non–small-cell lung cancer whose ...
Article
- Author:
- Laura Nikolaides
Publish date: October 20, 2016
Olaratumab, a platelet-derived growth factor receptor-alpha blocking antibody, is the first new therapy approved in 40 years for the initial treatm...
News
- Author:
- Laura Nikolaides
Publish date: August 9, 2016
